Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit.

AIMS The long-term disposition of tacrolimus following kidney transplantation is characterized by a gradual decrease in dose requirements and increase in dose-corrected exposure. This phenomenon has been attributed to a progressive decline in cytochrome P450 3A4 (CYP3A4) activity, although this has never been demonstrated in vivo. METHODS Sixty-five tacrolimus- and 10 cyclosporine-treated renal transplant recipients underwent pharmacokinetic testing at day 7 and months 1, 3, 6 and 12 after transplantation, including 8-h area under the concentration-time curve (AUC) for tacrolimus or cyclosporine and assessment of CYP3A4 activity using oral and intravenous midazolam (MDZ) drug probes. RESULTS Tacrolimus clearance decreased gradually throughout the entire first year but only in CYP3A5*3/*3 homozygous recipients (25.6 ± 11.1 l h(-1) at day 7; 17 ± 9.1 l h(-1) at month 12; P < 0.001). In mixed model analysis, decreasing CYP3A4 activity, measured by apparent oral MDZ clearance (924 ± 443 ml min(-1) at day 7 vs. 730 ± 344 ml min(-1) at month 1; P < 0.001), explained 55.4% of the decline in tacrolimus clearance in the first month. CYP3A4 activity decreased by 18.9 ml min(-1) for every milligram of methylprednisolone dose tapering within the first month; beyond this point it remained stable. A gradual rise in haematocrit throughout the entire first year explained 31.7% of the decrease in tacrolimus clearance in the first month and 23.6% of the decrease between months 1 and 12. Cyclosporine clearance did not change over time. CONCLUSIONS The maturation of tacrolimus disposition in the first year after renal transplantation observed in CYP3A5*3/*3 homozygous patients can partly be explained by a (steroid tapering-related) decline in CYP3A4 activity and a progressive increase in haematocrit.

[1]  L. Elens,et al.  The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients , 2014, The Pharmacogenomics Journal.

[2]  D. Kuypers,et al.  Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism. , 2013, Pharmacogenomics.

[3]  K. Verbeke,et al.  In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients , 2012, Clinical pharmacology and therapeutics.

[4]  A. Åsberg,et al.  Cyclosporine A- and Tacrolimus-Mediated Inhibition of CYP3A4 and CYP3A5 In Vitro , 2012, Drug Metabolism and Disposition.

[5]  V. Haufroid,et al.  A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. , 2011, Clinical chemistry.

[6]  K. Verbeke,et al.  A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma. , 2011, Biomedical chromatography : BMC.

[7]  K. Verbeke,et al.  In Vivo CYP3A Activity Is Significantly Lower in Cyclosporine‐Treated as Compared With Tacrolimus‐Treated Renal Allograft Recipients , 2011, Clinical pharmacology and therapeutics.

[8]  D. Cooper,et al.  Multi-center evaluation of a commercial Kit for tacrolimus determination by LC/MS/MS. , 2010, Clinical biochemistry.

[9]  Leslie Z Benet,et al.  The drug transporter-metabolism alliance: uncovering and defining the interplay. , 2009, Molecular pharmaceutics.

[10]  D. Kuypers,et al.  New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation , 2009, Therapeutic drug monitoring.

[11]  M. Sarwal,et al.  Maturation of Dose-Corrected Tacrolimus Predose Trough Levels in Pediatric Kidney Allograft Recipients , 2008, Transplantation.

[12]  J. D. de Fijter,et al.  CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients , 2008, Pharmacogenetics and genomics.

[13]  E. Lerut,et al.  CYP3A5 and CYP3A4 but not MDR1 Single‐nucleotide Polymorphisms Determine Long‐term Tacrolimus Disposition and Drug‐related Nephrotoxicity in Renal Recipients , 2007, Clinical pharmacology and therapeutics.

[14]  A. Edefonti,et al.  Influence of the Cyp3a5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients , 2007, Pediatric transplantation.

[15]  Edward Cole,et al.  Therapeutic monitoring of calcineurin inhibitors for the nephrologist. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[16]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[17]  M. Hebert,et al.  EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO , 2006, Drug Metabolism and Disposition.

[18]  J. Trotter,et al.  Immunosuppression: Evolution in Practice and Trends, 1994–2004 , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  Michael Oellerich,et al.  Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. , 2005, Clinical chemistry.

[20]  L. Benet,et al.  Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. , 2004, International journal of pharmaceutics.

[21]  U. Christians,et al.  CYP3A4-Transfected Caco-2 Cells as a Tool for Understanding Biochemical Absorption Barriers: Studies with Sirolimus and Midazolam , 2004, Journal of Pharmacology and Experimental Therapeutics.

[22]  P. Beaune,et al.  Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  W. Weimar,et al.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.

[24]  J. Hooff,et al.  Increase in tacrolimus trough levels after steroid withdrawal , 2003, Transplant international : official journal of the European Society for Organ Transplantation.

[25]  P. Syrris,et al.  Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement , 2002, Transplantation.

[26]  S. Kaneko,et al.  Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-Glycoprotein after high-dose steroid therapy , 2002, Transplantation.

[27]  C. Lindley,et al.  In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone , 2000, Clinical pharmacology and therapeutics.

[28]  D. Greenblatt,et al.  Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole , 1999, Clinical pharmacology and therapeutics.

[29]  J. Gorski,et al.  The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin , 1998, Clinical pharmacology and therapeutics.

[30]  Hébert.  Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. , 1997, Advanced drug delivery reviews.

[31]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.

[32]  T. Starzl,et al.  Clinical Pharmacokinetics of Tacrolimus , 1995, Clinical pharmacokinetics.

[33]  W. Trager,et al.  Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. , 1994, The Journal of pharmacology and experimental therapeutics.

[34]  Y. Tanigawara,et al.  Human P-glycoprotein transports cyclosporin A and FK506. , 1993, The Journal of biological chemistry.

[35]  T. Aoyama,et al.  Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. , 1989, The Journal of biological chemistry.

[36]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[37]  B. Maes,et al.  Time-Related Clinical Determinants of Long-Term Tacrolimus Pharmacokinetics in Combination Therapy with Mycophenolic Acid and Corticosteroids , 2004, Clinical pharmacokinetics.

[38]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation , 2004, Clinical pharmacokinetics.

[39]  Leslie Z. Benet,et al.  Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.